Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (501)	5/1/2003 8:02:02 PM
From: Biomaven	Read Replies (1) \| Respond to of 897

I can't see their drug 'working' in a short's timeframe. Probably correct, but imagine if they show it "works" in an in vitro experiment. That might happen pretty quickly. Peter

To: nigel bates who wrote (501)	6/2/2003 4:38:02 PM
From: tuck	Read Replies (2) \| Respond to of 897

Nigel, I'm putting RNAI in the WatchList, and will short it tomorrow, unless someone stops me. They'll need to finance long before they get anything in the clinic, VC control some 86% of the stock at much cheaper prices. Fresh grants of warrants and options, forgiven loans, wow. I cannot find the terms of the warrants, nor any lock-up agreement on all those shares the VC now hold. If anyone can find that information, please post it here. this has come way to far too fast on hype, IMO. On top of the overhang and financial risks, there's the IP issue. RNAi IP is still quite murky. Delivery of siRNA is currently problematic in mammalian cells. Today it seemed to be riding on the general hype of the promise of anti-angiogenesis & ASCO, though I know of no presentations by the company there . . . Cheers, Tuck